Accelerate Diagnostics (NASDAQ:AXDX) Releases Earnings Results, Beats Estimates By $0.13 EPS

Accelerate Diagnostics (NASDAQ:AXDX) announced its earnings results on Thursday. The medical research company reported ($0.37) EPS for the quarter, beating the consensus estimate of ($0.50) by $0.13, Zacks reports. The business had revenue of $2.82 million for the quarter, compared to the consensus estimate of $3.00 million.

Accelerate Diagnostics Stock Performance

Shares of Accelerate Diagnostics stock traded down $0.07 during trading hours on Friday, hitting $1.06. The company’s stock had a trading volume of 156,774 shares, compared to its average volume of 59,715. The company has a market cap of $26.55 million, a PE ratio of -0.37 and a beta of 0.55. Accelerate Diagnostics has a 12-month low of $0.73 and a 12-month high of $2.09. The business has a 50 day moving average price of $1.16 and a two-hundred day moving average price of $1.45.

Wall Street Analysts Forecast Growth

Several research firms have commented on AXDX. BTIG Research upgraded shares of Accelerate Diagnostics to a “strong-buy” rating in a research note on Wednesday, December 11th. StockNews.com initiated coverage on shares of Accelerate Diagnostics in a research report on Monday, March 17th. They set a “hold” rating for the company.

About Accelerate Diagnostics

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.